# A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Source: https://onco.cc/trials/nct06929624/  
OnCo record `nct06929624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing SHR-A1912 in diffuse large B-cell lymphoma, now recruiting.

## Summary

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT06929624, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-label, Randomised Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Planned enrolment is 280 participants (estimated). The study started in 2025-04-24 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06929624
- Phase: 3
- Setting: A Phase 3, Open-label, Randomized Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Sponsor: Suzhou Suncadia Biopharmaceuticals
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT06929624: https://clinicaltrials.gov/study/NCT06929624

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [SHR-A1912](https://onco.cc/drugs/shr-a1912/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06929624.json